Zelboraf and Macular oedema - a phase IV clinical study of FDA data

Summary:

Macular oedema is reported as a side effect among people who take Zelboraf (vemurafenib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Cotellic, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Macular oedema when taking Zelboraf. It is created by eHealthMe based on reports of 8,381 people who have side effects when taking Zelboraf from the FDA, and is updated regularly.

What is Zelboraf?

Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.

What is Macular oedema?

Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken) is found to be associated with 434 drugs and 860 conditions by eHealthMe. Check the latest studies of Macular oedema.

On Aug, 04, 2026

8,381 people reported to have side effects when taking Zelboraf.
Among them, 13 people (0.16%) have Macular oedema.

Among these 13 people:

How long have people been on Zelboraf when they have Macular oedema? *

What is the gender of people who have Macular oedema when taking Zelboraf? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Macular oedema when taking Zelboraf? *

What are other drugs people take besides Zelboraf? *

What are other side effects people have besides Macular oedema? *

Uveitis (inflammation of the uvea): 5 people, 38.46%
Concomitant Disease Aggravated (advanced due to some of accompanying): 4 people, 30.77%
Visual Impairment: 3 people, 23.08%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 23.08%
Detachment Of Retinal Pigment Epithelium: 2 people, 15.38%
Joint Pain: 2 people, 15.38%
Liver Disorder (liver diseases): 2 people, 15.38%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 2 people, 15.38%
Retinal Detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue): 2 people, 15.38%
Panniculitis (inflammation of the subcutaneous fat): 1 person, 7.69%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 7 people, 53.85%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 5 people, 38.46%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 2 people, 15.38%
Depression: 1 person, 7.69%
Birth Control: 1 person, 7.69%
Arrhythmias (irregular heartbeat): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Zelboraf and have Macular oedema?

- Check whether Macular oedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zelboraf:

Zelboraf (8,392 reports)

Macular oedema treatments and more:

Macular oedema (10,661 reports)

Browse all side effects of Zelboraf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Macular oedema:

Macular oedema (434 drugs)

Browse all the conditions that are associated with Macular oedema:

Macular oedema (860 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vemurafenib (the active ingredients of Zelboraf) and Zelboraf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.